國家衛生研究院 NHRI:Item 3990099045/12668

NHRI > Institute of Biotechnology and Pharmaceutical Research > Chiung-Tong Chen > Periodical Articles > Item 3990099045/12668

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12668

Title:	Artificial intelligence approach fighting COVID-19 with repurposing drugs
Authors:	Ke, YY;Peng, TT;Yeh, TK;Huang, WZ;Chang, SE;Wu, SH;Hung, HC;Hsu, TA;Lee, SJ;Song, JS;Lin, WH;Chiang, TJ;Lin, JH;Sytwu, HK;Chen, CT
Contributors:	Institute of Biotechnology and Pharmaceutical Research;Office of Environment, Safety, and Health;National Institute of Infectious Diseases and Vaccinology
Abstract:	Background :The ongoing COVID-19 pandemic has caused more than 193,825 deaths during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic medicine that has prior use experiences in patients in order to resolve the current pandemic situation before it could become worsening. Artificial intelligence (AI) technology is hereby applied to identify the marketed drugs with potential for treating COVID-19. Methods: An AI platform was established to identify potential old drugs with anti-coronavirus activities by using two different learning databases; one consisted of the compounds reported or proven active against SARS-CoV, SARS-CoV-2, human immunodeficiency virus, influenza virus, and the other one containing the known 3C-like protease inhibitors. All AI predicted drugs were then tested for activities against a feline coronavirus in in vitro cell-based assay. These assay results were feedbacks to the AI system for relearning and thus to generate a modified AI model to search for old drugs again. Results: After a few runs of AI learning and prediction processes, the AI system identified 80 marketed drugs with potential. Among them, 8 drugs (bedaquiline, brequinar, celecoxib, clofazimine, conivaptan, gemcitabine, tolcapone, and vismodegib) showed in vitro activities against the proliferation of a feline infectious peritonitis (FIP) virus in Fcwf-4 cells. In addition, 5 other drugs (boceprevir, chloroquine, homoharringtonine, tilorone, and salinomycin) were also found active during the exercises of AI approaches. Conclusion: Having taken advantages of AI, we identified old drugs with activities against FIP coronavirus. Further studies are underway to demonstrate their activities against SARS-CoV-2 in vitro and in vivo at clinically achievable concentrations and doses. With prior use experiences in patients, these old drugs if proven active against SARS-CoV-2 can readily be applied for fighting COVID-19 pandemic.
Date:	2020-08
Relation:	Biomedical Journal. 2020 Aug;43(4):355-362.
Link to:	http://dx.doi.org/10.1016/j.bj.2020.05.001
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2319-4170&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000579445300009
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85085932433
Appears in Collections:	[Chiung-Tong Chen] Periodical Articles [Shiow-Ju Lee] Periodical Articles [John Tsu-An Hsu] Periodical Articles [Teng-Kuang Yeh] Periodical Articles [Others] Periodical Articles [Huey-Kang Sytwu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB32426387.pdf		1251Kb	Adobe PDF	370	View/Open

Loading...